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Background: Interventions to protect young infants against respiratory syncytial virus (RSV) are in
advanced phases of development and are expected to be available in the foreseeable future. Gavi, the
Vaccine Alliance, included maternal vaccines and infant monoclonal antibodies for RSV as part of the
2018 vaccine investment strategy (VIS) and decided to support these products subject to licensure,
World Health Organization prequalification, Strategic Advisory Group of Experts recommendation, and
meeting the financial assumptions used as the basis of the investment case. Impact estimates reported
in this manuscript were used to inform the Gavi VIS.
Methods: We compared two independent vaccine impact models to evaluate a potential maternal RSV
vaccine’s impact on infant health in 73 Gavi-supported countries. Key inputs were harmonized across
both models. We analyzed various scenarios to evaluate the effect of uncertain model parameters such
as vaccine efficacy, duration of infant protection, and infant disease burden. Estimates of averted cases,
severe cases, hospitalizations, deaths, and disability-adjusted life years (DALYs) were calculated over
the 2023–2035 horizon.
Findings: A maternal RSV vaccine with 60% efficacy offering 5 months of infant protection implemented
across 73 low- and middle-income countries could avert 10.1–12.5 million cases, 2.8–4.0 million hospi-
talizations, 123.7–177.7 thousand deaths, and 8.5–11.9 million DALYs among infants under 6 months of
age for the duration of analysis (2023–2035). Maternal RSV vaccination was projected to avert up to 42%
of estimated RSV deaths among infants under 6 months in year 2035. Alternative scenario analyses with
higher disease burden assumptions showed that a maternal vaccine could avert as many as 325–355
thousand deaths among infants under 6 months.
Interpretation: RSV maternal immunization is projected to substantially reduce mortality and morbidity
among young infants if introduced across Gavi-supported countries.
Funding: This work was supported by Bill & Melinda Gates Foundation, Seattle, WA, and Respiratory
Syncytial Virus Consortium in Europe. The findings and conclusions contained within are those of the
authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation or of
the Respiratory Syncytial Virus Consortium. LW is supported by Research Foundation–Flanders
(1234620 N).
 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Under-5 mortality declined by 59% globally between 1990 and
2018 [1]. Despite this impressive reduction, the pace of decline
5140 R. Baral et al. / Vaccine 38 (2020) 5139–5147has not been as rapid for infants and neonates. In 2018, approxi-
mately 70% and 47% of deaths in children under 5 years of age
occurred among infants and neonates, respectively [1]. Addressing
disease burden among this age group is imperative to achieving the
Sustainable Development Goal of ending preventable deaths in
newborns and children under 5 years of age [1,2].
A significant proportion of morbidity and mortality during the
first year of life is due to infectious diseases [3,4]. Although many
of these diseases are vaccine preventable, protecting a newborn
with active immunization is not always possible as the newborn’s
immune response system continues to develop and particularly
when multiple doses are required over weeks or months [5]. One
alternative to combat neonatal and early infant mortality is to vac-
cinate pregnant women. Most adults have been primed by natural
infection with respiratory syncytial virus (RSV). Upon vaccination
the mother’s antibodies are boosted and are transferred to the
fetus to provide protection during the infant’s first months of life.
Maternal immunization (MI) is gaining support, especially follow-
ing the success of MI strategies to reduce the burden of neonatal
tetanus, infant pertussis, and maternal and infant influenza [6].
RSV, a common cause of acute lower respiratory infections
(ALRIs), disproportionately impacts infants in their first months
of life [3,4]. Globally, RSV-associated ALRIs are responsible for an
estimated 118,000 annual deaths among children under 5 years
[7]. About 46% of those deaths are estimated to occur among chil-
dren<6 months of age [7]. This burden predominantly affects chil-
dren in low- and middle-income countries (LMICs), where
approximately 90% of RSV-associated ALRI mortality occurs. Cur-
rent preventive and treatment options for RSV are costly, but mul-
tiple RSV interventions are in development with licensure of
maternal vaccines and long-lasting infant monoclonal antibodies
(mAbs) anticipated in the coming years [8].
Some of the RSV interventions under development, including
vaccines for pregnant women and infant mAbs, were considered
by Gavi, the Vaccine Alliance, in its 2018 Vaccine Investment Strat-
egy (VIS) for the 2021–2025 funding period. The VIS occurs every
five years and allows Gavi to prioritize new investments for its
next strategic and funding cycle. Health impact as measured by
cases and deaths averted is one of the main criteria Gavi uses to
prioritize interventions. This paper presents model-based esti-
mates of the potential health impact of RSV maternal immuniza-
tion (RSV MI) in Gavi-supported countries, which were generated
independently to inform Gavi’s decision-making on maternal RSV
vaccination in its funding portfolio. Gavi’s VIS analysis for RSV
interventions included multiple phases of evaluation of assump-
tions, scenarios, and independent modeling outputs by expert
groups from June 2017 to June 2019. The scenarios and results dis-
cussed in this paper include those prepared for the VIS as well as
those considering alternative disease burden assumptions based
on expert input regarding emerging yet unpublished data and
recent vaccine clinical trial results that were not available in time
to inform the VIS. Importantly, the results presented here only rep-
resent impact on RSV in young infants and do not incorporate the
substantial impact vaccination would likely have on all infant
lower respiratory tract infections, as suggested by recent studies
[9,10].2. Methods
Several models of RSV MI were independently developed by
distinct groups to allow for cross-validation and to assess the
potential impact of uncertainty related to model structure choices.
To guide model development, the Gavi Secretariat convened a ser-
ies of consultations and discussion meetings with select expert
groups and stakeholders (see Appendix Table 1 for full list) toassess and align on methods, assumptions, data inputs, country
vaccine introduction scenarios, and sensitivity analyses. Each mod-
eling group then separately analyzed the impact of RSV MI based
on the common set of inputs in order to inform Gavi’s assessment
of RSV as part of the VIS. This paper includes results from two of
the RSV MI models (PATH and the University of Antwerp in part-
nership with the London School of Hygiene & Tropical Medicine
[hereafter referred to as UA]) and a subset of scenarios used to
inform the Gavi 2018 VIS.
2.1. Model
Both RSV MI models are static cohort models that follow a com-
mon structure (Appendix Fig. 1) and compare the annual impact of
vaccinating pregnant women against RSV to protect infants up to
6 months of age compared to an alternative of no RSV MI. We
assumed single-dose year-round vaccination of pregnant women
during established antenatal care (ANC) visits. All pregnant women
attending ANC between 24 and 36 weeks of gestation were
assumed eligible for vaccination.
Common model outcomes were non-severe episodes, hospital-
izations, deaths, and disability-adjusted life years (DALYs) averted
among infants by vaccinating pregnant women across 73 LMICs
between 2023 and 2035. The PATH model also estimated severe
episodes of RSV among infants. The year of introduction for each
country was based on product development, global policy timeline
projections at the time of the analysis, and Gavi country introduc-
tion year assumptions for vaccines under consideration in the VIS.
In order to compare results across potential additions to Gavi’s
investment portfolio, the health outcome estimates presented in
this paper are not discounted.
2.2. Key data inputs and assumptions
The modeling groups harmonized key model parameters to
support comparability of results, including demography, vaccine
characteristics, estimated country introduction dates, and vaccine
delivery scenarios. A list of shared input parameters and sources
is provided in Table 1. Modeling groups used the same source for
disease burden data but made different methodological decisions
about how to incorporate these data to account for insufficient
granularity and source data presentation that diverged frommodel
input requirements.
2.2.1. Disease burden
Both models estimated RSV infant disease burden based on a
recent systematic review [7]. Key burden inputs included rates of
incidence, severe incidence, hospitalizations, and mortality, as
defined in the literature. Country-specific estimates of RSV inci-
dence among children 0 to 5 years were used for 63 of 73 countries
(86%) included in the analysis. Where country-specific data were
not available, the PATH model applied an average of the estimates
from other countries in the same income group per World Bank’s
definition and within the same geographic region [16]. The UA
model bridged the estimates from countries in the same geo-
graphic regions with similar infant and under-5 mortality rates
(Appendix Table 3.3).
While both models relied on the same data source for input
parameters, there were key differences in the application of these
parameters (Appendix Table 2). For example, age-stratified inci-
dence estimates in the literature have insufficient age granularity
to discern meaningful differences by age group as well as by
region/country. Each modeling group addressed this challenge sep-
arately—the UA model fitted a spline to interpolate the age-specific
data, whereas the PATH model assumed constant incidence within
Table 1
Primary inputs harmonized across models.
Input Value Sources
Target
population
by country
Approximately 90 million
pregnant women
globally, per year
United Nations Population
Database, 2017 and Lawn
et al., 2016 [11,12]
Vaccine
schedule
Single dose provided
year-round as part of ANC
services
Preferred Product
Characteristics [13]; expert
opinion
Vaccination
window
24–36 weeks of gestation Preferred Product
Characteristics [13]; expert
opinion
Vaccine
coverage by
country
Average in year 2023,
69% (21%–96%)
DHS and WHO [14,15]
Vaccine
introduction
dates by
country
Phased, 2023 to 2035 Product development
timeline [8]; prior vaccine
introduction
Vaccine efficacy
for infant
protection
Midpoint 60% Preferred Product
Characteristics [13]; expert
opinion
Duration of
protection
Midpoint 5 months, no
waning before 5 months
Preferred Product
Characteristics [13]; expert
opinion
Abbreviations: ANC, antenatal care; DHS, Demographic and Health Surveys; WHO,
World Health Organization.
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cases among children 0 through 5 years (see Appendix Table 2).
Disease burden estimates, especially in low-income settings,
are generally derived from hospital-based data [7]. However, the
number of unreported RSV cases and deaths in the community is
largely unknown [17]. Both models therefore adjusted for unre-Table 2
Input parameters for RSV disease burden in children.
Parameter UA
Annual incidence of RSV-ALRI per 1,000 children under 5 Country-specific estimates
(35.3 to 65.6)
Annual incidence of RSV-ALRI per 1,000 children under 5,
by age group
Developing country estim
0–27 days 40.0
28–< 3 months 45.7
3–5 months 99.6
6–11 months 98.8
12–23 months 79.1
Annual incidence of severe RSV-ALRI per 1,000 children
under 5, by age group
Not included due to
insufficient age-specific da
0–5 months NA
6–11 months NA
0–59 months NA
Annual hospital admissions for RSV-associated ALRI per
1,000 children under 5, by age group
Developing country estim
0–5 months 0–27 days: 15.9;
28 days–3 months: 26.1;
3–5 months: 20.7
6–11 months 6–8 months: 12;
9–11 months: 11.3
Hospital case fatality risk (%), by age group Developing country estim
0–5 months 0–27 days: 5.3;
28 days–3 months: 2.3;
3–5 months: 2.4
6–11 months 6–8 months: 3.0;
9–11 months: 3.6
Disability weight for DALY calculation
Severe ALRI 0.21
Non-severe ALRI 0.053
Duration of illness (days) 11.2
Abbreviations: ALRI, acute lower respiratory infection; DALY, disability-adjusted life yea
partnership with the London School of Hygiene & Tropical Medicine. Table numbers repreported community deaths using mortality multipliers as suggested
in the literature [7]. Input parameter values for disease burden uti-
lized by each model are presented in Table 2.2.2.2. Vaccine characteristics
Vaccine characteristics including the duration of protection in
infants and vaccine efficacy used for modeling were informed by
WHO’s RSV maternal vaccine Preferred Product Characteristics
(PPC) with additional perspectives from a group of RSV experts
coordinated by Gavi to inform the vaccine investment strategy.
WHO PPC indicate a vaccine with 50% efficacy and duration of pro-
tection of 3 months as acceptable and a product with >70% efficacy
and > 4 months as preferred. For the baseline scenario, we used a
5 months duration of protection and 60% vaccine efficacy and eval-
uated a range of values to test the impact of uncertain input
parameters in the scenario analysis.2.2.3. Target population, coverage, and country vaccine introduction
Both models used the same target population and coverage rate
for each country. The number of pregnant women eligible for vac-
cination, by country, was derived from the World Population Pro-
spects’ annual birth projections and country-specific projected
population growth rates [12]. Annual birth projections were
adjusted by country-specific stillbirth rates [11], yielding the total
number of pregnant women in each country.
The RSV maternal vaccine was modeled to be delivered year-
round in a single dose between 24 and 36 weeks of gestation,
requiring data on the timing of ANC visits or contacts by gesta-
tional age. These data are not widely available in LMICs, so vaccine
coverage estimates were modeled for each country based on
reported ANC coverage, the projected timing of ANC visits, andPATH Source
Country-specific
estimates (35.3 to 65.6)
[7, Supplementary Table 18*]
ate Developing country
estimate
[7, supplementary Table 9*]
40.0
45.7
99.6
98.8
79.1
ta
Developing country
estimate
[7, Table 1*]
36.1
24.7
10.2
ate Developing country
estimate
[7, Supplementary Table 20 for UA estimate,
and Table 1 for PATH estimate*]
20.2
11
ate Developing country
estimate
[7, Supplementary Table 20 for UA estimate,
and Table 2 for PATH estimate*]
2.2
2.4
[18]
0.21
0.053
11.2 [19]
r; NA, not applicable; RSV, respiratory syncytial virus; UA, University of Antwerp in
sent tables from the source literature [7] from where the input values were derived.
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estimated in 2017 and projected to increase in subsequent years
to be consistent with modeling for childhood vaccines being con-
sidered for Gavi’s portfolio. We assumed that coverage increased
by three percentage points per year up to 70%, after which it
increased by one percentage point per year until reaching 95%,
consistent with other vaccine models considered in the VIS [20].
The Appendix Fig. 2 details steps used to model eligibility and vac-
cination coverage during the vaccination window.
Both models assumed the vaccine would be available, with no
supply constraint, for introduction in Gavi-supported countries
by 2023 based on the status of clinical studies of lead vaccine can-
didates at the time of analysis and accounting for time required for
licensure and World Health Organization (WHO) prequalification
[8]. Introduction of the vaccine across 73 Gavi-supported/
formerly supported countries (hereafter ‘‘Gavi countries”) was
modeled to be phased between 2023 and 2035. A description of
introduction timelines is available in the Appendix Table 3.2.2.2.4. Sensitivity and scenario analysis
There is wide uncertainty around various input parameters,
particularly disease burden and vaccine characteristics like efficacy
and duration of protection. To address this challenge, we con-
ducted a series of one-way sensitivity analyses where we varied
selected model parameters across a plausible range to assess each
parameter’s influence on model results. Both models used common
uncertainty ranges for each parameter to conduct model sensitiv-
ity. Maternal vaccine efficacy was modeled to a range between
30% and 90% and duration of infant protection was modeled to last
between 4 and 6 months. We also conducted scenario analyses
where vaccine efficacy and duration of protection were simultane-Table 3
List of scenarios modeled.
# Scenario Vaccine efficacy DOP
(months)
Disease bu
1 Baseline (VE 60%, DOP 5 m) 60% (constant for all
outcomes)
5 [7]
2 Baseline VE (60%) and
minimum DOP (4 m)
60% (constant for all
outcomes)
4 [7]
3 Baseline VE (60%) and
maximum DOP (6 m)
60% (constant for all
outcomes)
6 [7]
4 Minimum (VE 30%, DOP
4 m)
30% (constant for all
outcomes)
4 [7]
5 Minimum VE (30%) and
baseline DOP (5 m)
30% (constant for all
outcomes)
5 [7]
6 Minimum VE (30%) and
maximum DOP (6 m)
30% (constant for all
outcomes)
6 [7]
7 Maximum (VE 90%, DOP
6 m)
90% (constant for all
outcomes)
6 [7]
8 Maximum VE (90%) and
minimum DOP (4 m)
90% (constant for all
outcomes)
4 [7]
9 Maximum VE (90%) and
baseline DOP (5 m)
90% (constant for all
outcomes)
5 [7]
10 Prepare trial primary
results VE and DOP
Cases = 39.4%;
Hospitalization = 44.4%;
Death = 48.3%
3 [7]
11 Prepare trial expanded
results VE and DOP
Cases = 40.9%;
Hospitalization = 41.7%;
Death = 59.6%
3 [7]
12 Prepare trial primary
results VE and DOP, under
high burden
Cases = 39.4%;
Hospitalization = 44.4%;
Death = 48.3%
3 8.7% of all
RSV, as sug
[21,22]
13 Prepare trial expanded
results VE and DOP, under
high burden
Cases = 40.9%;
Hospitalization = 41.7%;
Death = 59.6%
3 8.7% of all
RSV, as sug
[21,22]
14 Baseline VE and DOP,
under high burden
60% (constant for all
outcomes)
5 8.7% of all
RSV, as sug
[21,22]
Abbreviations: DOP, duration of protection; VE, vaccine efficacy; LRTI, lower respiratoryously varied to evaluate the potential combined impact on health
outcomes. Additionally, we estimated the impact of MI under a
high disease burden scenario as suggested by recent surveillance
studies [21,22]. Finally, as an adjunct to the information provided
to Gavi, we formed an additional scenario using vaccine efficacy
data from the Phase 3 trial of a lead maternal vaccine candidate
[9]. A list of all scenarios and their descriptions is provided in
Table 3. A subset of these scenarios was used to inform the Gavi
VIS. In particular, Gavi assumed a vaccine efficacy range of 50%–
90% and corresponding duration of protection of 3 to 6 months.
Additionally, Gavi prioritized model results for the subset of coun-
tries that were projected to remain eligible for new vaccine sup-
port when RSV interventions are available. Also, Gavi used a
pooled analysis that included the third model not included in this
manuscript [23].3. Results
Projected health outcomes averted among infants under
6 months of age after the introduction of RSV MI in 73 Gavi coun-
tries between 2023 and 2035 are provided in Table 4, by model and
averaged across both models. In the baseline scenario, the mater-
nal RSV vaccine is estimated to avert an average of 11.3 million
RSV cases (inter-model range: 10.1 to 12.6 million). Additionally,
we project that more than 3.4 million hospitalizations (inter-
model range: 2.8 to 4.0 million), 150 thousand deaths (inter-
model range: 124 to 178 thousand), and 10.3 million DALYs
(inter-model range: 8.6 to 12.0 million) would be averted across
all years. By 2035, on average, we project that 41% to 42% of annual
RSV deaths in infants under 6 months in the 73 countries would be
averted. In a cohort of 100,000 vaccinated pregnant women, therden Source
Assumptions
Assumptions
Assumptions
Assumptions
Assumptions
Assumptions
Assumptions
Assumptions
Assumptions
Prepare trial results (Phase 3), based on primary
analysis that uses per protocol population [9]
Prepare trial results (Phase 3), based on expanded
analysis that includes additional population excluded
per protocol [9]
LRTI deaths attributed to
gested by new evidence
Prepare trial results (Phase 3), based on primary
analysis that uses per protocol population [9]
LRTI deaths attributed to
gested by new evidence
Prepare trial results (Phase 3), based on expanded
analysis that includes additional population excluded
per protocol [9]
LRTI deaths attributed to
gested by new evidence
Base case vaccine efficacy and duration of protection
under a high burden scenario
tract infection; m, month.
Table 4
Estimates of health impacts in 73 Gavi countries in year 2023–2035 for the baseline
scenario.
RSV associated UA PATH Average
across
models
Total RSV cases averted^ 10,106,070
(3,493,773–
20,811,437)
12,553,081
(4,385,604–
24,456,864)
11,329,575
Non-severe cases averted 6,053,139
(1,880,906–
13,775,109)
8,868,303
(2,911,693–
18,173,349)
7,460,721
Severe cases averted NA 3,684,778
(1,473,911–
6,283,516)
3,684,778
Hospital admissions averted 4,052,931
(1,612,867–
7,036,328)
2,840,087
(1,136,035–
4,724,105)
3,446,509
Deaths averted 177,717
(70,418–
309,811)
123,714
(49,486–
207,619)
150,716
YLDs averted 35,963
(13,439–
67,740)
37,369
(13,914–
68,707)
36,666
YLLs averted 11,927,676
(4,724,075–
20,806,417)
8,520,783
(3,408,313–
14,299,729)
10,224,230
DALYs averted* 11,963,639
(4,737,529–
20,874,133)
8,558,152
(3,422,227–
14,368,437)
10,260,896
Number needed to vaccinate to
avert a death
3,339
(1,915–
8,426)
4,796
(2,858–
11,990)
4,067
Infant cases averted per 100,000
vaccinated pregnant women
1,703
(589–
3,507)
2,116
(739–
4,122)
1,909
Infant deaths averted per 100,000
vaccinated pregnant women
30
(12–52)
21
(8–35)
25
Proportion of RSV deaths averted
among children < 6 months
(total)
0.27
(0.11–0.46)
0.27
(0.11–0.46)
0.27
Proportion of RSV deaths averted
among children < 6 months (in
2035)
0.41
(0.16–0.71)
0.42
(0.17–0.70)
0.42
Abbreviations: DALY, disability-adjusted life year; NA, not applicable; RSV, respi-
ratory syncytial virus; UA, University of Antwerp in partnership with the London
School of Hygiene & Tropical Medicine; YLD, years lived with disability; YLL, years
of life lost.
Baseline scenario applied vaccine efficacy of 60% and 5 months duration of pro-
tection. Values in parenthesis represent estimates from minimum (Scenario 4) and
maximum (Scenario 7) scenarios.
^ UA model applied: Total RSV cases = non-severe cases + hospital admissions.
PATH model applied: Total RSV cases = non-severe + severe cases.
* Undiscounted DALYs are used.
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model range: 1,700 to 2,100) of RSV and 25 infant deaths (inter-
model range: 21 to 30).
Distribution of total deaths averted, and the number of deaths
averted per 100 thousand vaccinated pregnant women, under the
baseline scenario, for year 2035, is shown in Fig. 1. Although coun-
tries with larger birth cohorts (for example, India) are predicted to
have a larger impact in terms of absolute number of deaths averted
(panel a), impact of vaccination that takes into account the relative
coverage (defined as deaths averted per 100 thousand vaccinated
women) reflects a more even distribution of impact (panel b).
Appendix Tables 4.1–4.3 contain country-specific estimates of dis-
ease burden and expected health impact of the vaccine.
Fig. 2 shows the average predicted number of deaths due to RSV
among children under 6 months and the estimated average deaths
averted due to RSV MI stratified by region, World Bank income
group, and country’s expected Gavi transition status [24]. We
found that more than 80% of the vaccine impact would occuramong countries in sub-Saharan Africa and South Asia, the regions
that comprise the largest estimated disease burden as well as
countries receiving Gavi support. When average model results
were stratified based on each country’s projected Gavi financing
status in 2023, we find more than a quarter (28%) of the impact
is expected among countries in the initial self-financing phase,
13% in the preparatory transition phase, and 15% in the accelerated
transition phase. Since many of the countries included in our anal-
ysis are expected to transition from Gavi support in the later years
of the analysis, much of the impact (43%) would be among fully
self-financing countries that no longer receive Gavi support.3.1. Sensitivity and scenario analysis
We conducted one-way sensitivity analyses to assess the
impact of individual parameters on our estimates of health impact.
Given that vaccine efficacy and duration of infant protection are
uncertain, we modeled a range of scenarios to understand the
potential impact on model outcomes. Additional scenarios using
latest clinical trial data [9] and higher disease burden were also
modeled (see Table 3 for scenario description).
Fig. 3 shows the averted disease burden among infants achieved
by vaccinating pregnant women over different assumptions of effi-
cacy and duration of protection and scenarios. The estimated bur-
den averted monotonically increases with higher efficacy and
longer duration of protection. For example, assuming 90% efficacy
with 6 months of protection (Scenario 7) is estimated to result in
more than four times higher impact in terms of deaths averted
compared to a vaccine with 30% efficacy and 4 months of protec-
tion (Scenario 4), and roughly twice the impact compared to 60%
efficacy and 5 months of protection (Scenario 1, baseline). Com-
pared to the baseline scenario (Scenario 1, baseline) deaths averted
are more than double in higher mortality burden scenario (Sce-
nario 14), ceteris paribus.
Using the PrepareTM Phase 3 clinical trial vaccine efficacy data
(Scenarios 10 and 11), our models predict roughly 3.0 to 3.46 mil-
lion cases averted, 1.2 to 1.6 million averted hospitalizations, and
about 60,000 to 95,000 deaths averted across all countries and
years considered. A maternal vaccine with efficacy values compa-
rable to Prepare Phase 3 trial results is projected to achieve about
28% to 31% of averted cases, 40% to 44% of averted hospitalizations,
and 43% to 60% of averted deaths compared to the impact esti-
mated under the baseline scenario. Detailed results under all alter-
native scenarios are given in Appendix Tables 4.1–4.3 and
Appendix Figure 3.4. Discussion
Across two independent models, we projected that introduction
of RSV MI could substantially reduce the RSV burden among
infants under 6 months of age across 73 Gavi countries. In our mid-
point (baseline) scenario, we estimated 10 to 12 million RSV cases,
8.5 to 112 million DALYs, and 123,000 to 177,000 deaths could be
averted with the maternal RSV vaccine between 2023 and 2035
across 73 Gavi countries. Results from another RSV MI impact
model [23], which is consistent with the results from the models
included in this study, were also used to inform the VIS. The VIS
sets priorities for vaccine support programs in Gavi countries in a
transparent manner through evidence-based analysis and exten-
sive consultations [20].
A key strength of this work is independent estimation by mul-
tiple modeling groups, as recommended by WHO guidelines for
vaccine impact models [25–27], that allowed for the assessment
of ‘‘convergent validity” of multiple model estimates. While key
model inputs of vaccine characteristics and population demo-
Panel a: Distribuon of absolute number of deaths averted in year 2035 under baseline scenario 
(average esmates across two models). 
Panel b: Distribuon of deaths averted per 100,000 pregnant women vaccinated in year 2035 under 
baseline scenario (average esmates across two models). 
Fig. 1. Distribution of health impact of RSV MI in year 2035, under baseline scenario. Panel a: Distribution of absolute number of deaths averted in year 2035 under baseline
scenario (average estimates across two models). Panel b: Distribution of deaths averted per 100,000 pregnant women vaccinated in year 2035 under baseline scenario
(average estimates across two models).
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constructed and calibrated its model. A considerable range of
potential RSV MI impact estimates were generated under various
scenarios. The variations between the two model outcomes were
primarily due to differences in interpretation and interpolation of
data on age-specific RSV-associated disease burden [7]. A multiple
model comparison allowed for assessment of model consistency,
which is needed to improve credibility and to inform decision-
makers in a multicountry and multi-scenario analysis.
RSV MI in Gavi countries stands to prevent approximately 42%
of the RSV deaths among infants under 6 months of age that would
occur without the vaccine. A few studies on the impact of RSV MI
indicate about 32% reduction in RSV infections and about 50%
reductions in RSV hospitalizations among infants in Kenya
[28,29]. Despite the differences in underlying model and the
assumptions, our estimates are similar to the estimates of RSV
MI impact in LMIC settings. Our results are also comparable with
the projected impact of rotavirus vaccines, for instance, which
are predicted to avert 36% of rotavirus-related diarrheal deaths
among under 5 children across Gavi countries [30]. While the scaleof RSV impact is smaller than that for other blockbuster vaccines,
this is expected given the relative burden [31]. Lower projected
impact can also be viewed as a sign of progress given the success
of the global health community in reducing the burden of major
causes of child mortality [32]. Declines in overall child mortality
and a concentration of burden among the youngest infants also
points to the need to develop interventions to protect infants dur-
ing the first weeks of life before active infant vaccination can pro-
vide protection.
Maternal immunization against pertussis and influenza to pro-
tect mothers and young infants has proven effectiveness to protect
many newborns against these diseases in certain geographies and
is a useful reference for lessons learned [33–36]. In addition to
demonstrated impact of maternal immunizations, other maternal
vaccines are highlighting lessons that can be gleaned for preparing
health systems for new maternal vaccines [36]. RSV MI might be
one of the first vaccines given to pregnant women in LMICs for
the primary purpose of protecting young infants. This will be an
important milestone that illustrates an increasing focus on a life-
course approach to vaccination. RSV MI also represents opportuni-
Fig. 2. Average number of estimated deaths and deaths averted among < 6 months old (2023–2035) by region, income group, and Gavi eligibility status.
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health programs amid efforts to achieve universal health coverage
and the Sustainable Development Goals [36].
A lead maternal RSV vaccine candidate did not meet the study’s
primary endpoint, creating uncertainty about its licensure [9].
However, using topline efficacy results from the trial [9], our anal-
ysis shows the vaccine product would likely have a large impact on
RSV deaths. This suggests that modeling and clinical trial results
can better inform the potential for public health impact and
decision-making than clinical trial results alone.Fig. 3. One-way sensitivity analysis. Abbreviations: DB, disease burden (source 1 = Shi et
evidence [9]); DOP, duration of protection; m, month; PE, Prepare trial expanded efficacy
S, scenario; VE, vaccine efficacy.Our analyses have a few limitations, including model structure,
source data, and the scope of benefits included in our models. Both
models were static cohort-based models and, thus, do not capture
indirect effects such as preventing RSV infection between mothers
and other household members. We assume constant RSV burden
over the period of analysis.
RSV maternal vaccine coverage that needs administration dur-
ing a specific gestation window is largely unknown, especially
across LMICs. We therefore modeled vaccine coverage using
country-specific data on ANC visit timing [14] and WHO focusedal., 2017 [7]; source 2 = 8.7% of all LRTI deaths attributed to RSV, as suggested by new
results; PP, Prepare trial primary endpoint efficacy; RSV, respiratory syncytial virus,
5146 R. Baral et al. / Vaccine 38 (2020) 5139–5147antenatal care (FANC) guidance on timing of ANC visits [37]. The
newer WHO guidance on ANC [15] suggests a higher number of
visits/contacts than considered in the FANC model, which suggests
our vaccine coverage estimates may be underestimates as the
number of ANC contacts increase. Further, the impact estimates
reported in this analysis do not include the full potential impact
as countries are assumed to introduce vaccines in different years
and earlier introduction would imply higher impact than reported
here. On the other hand, our impact estimates are sensitive to
annual increase in coverage assumption, especially for countries
with low predicted coverage in the first year of introduction. For
example, vaccine coverage for Burundi in 2023 is predicted to be
about 44%, but by the end of 2035 it is predicted to reach 74%.
The impact of this linear increase in vaccine coverage assumption
means the share of burden averted in Burundi reaches from 15%
in 2023 to about 31% in 2035. More importantly, the investments
that would be required to strengthen the health systems that are
able to achieve this level of coverage and therefore the stated level
of vaccine impact is likely not insignificant.
Our baseline scenario assumes vaccines’ performance that
exceeds that from some existing maternal vaccines against other
pathogens [38] and RSV MI clinical trial data available to date
[39]. However, we anticipate that a product that could be sup-
ported by donors for broader use in the LMICs will need to offer
efficacy and duration of protection in infants comparable to that
indicated in the PPC [13]. The estimates across multiple scenarios
capture the uncertainty of unknown product characteristics. On
the other hand, children with higher risk of severe RSV disease,
such as prematurely born children, may benefit differently from
RSV maternal vaccine compared to the full-term infants. We do
not account for any potential differences in this population due
to data limitations. As a result, our models potentially bias the
impact in the preterm population, especially in low-income coun-
tries with higher rates of premature births [40].
There is a dearth of RSV burden data from LMICs, and though we
believe we have used the best published estimates, they are sub-
ject to uncertainty. Community-based surveillance studies suggest
the real burden of RSV is much higher than reported in these pre-
dominantly hospital-based studies, with RSV being associated with
as much as 8% to 11% of all lower respiratory tract deaths in some
countries [21,41,42]. In a scenario where RSV is associated with
8.7% of all causes of lower respiratory infection deaths (Scenario
14), our models estimated roughly two-to-three times the mortal-
ity averted using the primary source of disease burden data. More-
over, there is some evidence in the literature that suggests
acquiring RSV disease is associated with wheezing, asthma, or
other reduced pulmonary function later in life [43–45]. This link
is not yet viewed as conclusive, so long-term sequelae were
excluded from our analyses, as were potential maternal benefits
of vaccination such as enhanced infant protection through breast-
feeding, preventing inappropriate antibiotic use and thus antimi-
crobial resistance, reducing treatment demands on the health
system, and other socioeconomic benefits of RSV prevention.
Finally, recent trial data for a lead maternal RSV vaccine candidate
were not fully incorporated into this analysis for Gavi VIS decision-
making. While the topline trial data demonstrate a higher efficacy
against severe diseases outcomes compared to our baseline analy-
sis, they also indicate relatively lower efficacy estimates for other
disease endpoints [9]. However, the current trial results available
for maternal vaccine also claim significant efficacy in reducing all
respiratory hospitalizations and reduction in all cause severe
hypoxemia through the first 6 months of life, critical non-RSV out-
comes that were not included in our model.
The modeling work presented here represents collaborative
efforts to fill important knowledge gaps for global health agencies
such as Gavi and WHO and country-level stakeholders that arebeginning to prioritize and plan for future vaccine introductions
while vaccines are still in the development pipeline. Our study
demonstrates that introduction of maternal RSV MI in low- and
middle-income countries would greatly reduce mortality among
the youngest infants. Most importantly, this analysis was a critical
input for Gavi’s decision to support RSV maternal immunization
products subject to licensure, WHO prequalification, Strategic
Advisory Group of Experts recommendation, and meeting the
financial assumptions used as the basis of the investment case.
Future research should explore the relative effectiveness as well
as cost-effectiveness of the RSV MI strategy compared to the other
preventive strategies against infant RSV.Funding
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